Federal guidelines on diagnosis and treatment of chronic

Pulmonologiya 32, 356-392

DOI: 10.18093/0869-0189-2022-32-3-356-392

Citation Report

#	Article	IF	CITATIONS
1	Regulation and funding for home respiratory support and oxygen therapy strengthening the capacity. Medical Technologies Assessment and Choice (ĐœĐμĐĐ,цĐ,Đ½ÑĐºĐ,Đμ Ñ,ĐμÑĐ½Đ¾Đ»Đ¾Đ³Đ,Đ, ĐžÑ†Đ	ημ <b>Θ<sup>1</sup>/2</b> аĐ'	° Đ <sup>O</sup> ¸Đ²Ñ‹Đ±Đ <sup>;</sup>
2	Clinical and molecular features of virus-induced acute exacerbations of chronic obstructive pulmonary diseas. Meditsinskiy Sovet, 2022, 16, 30-39.	0.5	1
3	Chronic obstructive pulmonary disease and miocardial revascularisation outcomes: relationship with self-reported quality of life. Pulmonologiya, 2022, 32, 854-861.	0.8	0
4	Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice. Pulmonologiya, 2023, 33, 109-118.	0.8	2
5	Clinic and functional features of chronic obstructive pulmonary disease after virus-induced acute exacerbations Terapevticheskii Arkhiv, 2023, 95, 217-222.	0.8	2
6	Contribution of signaling pathways associated with cellular senescence and regulatory non-coding RNAs to chronic obstructive pulmonary disease. Genes and Cells, 2023, 18, 93-108.	0.2	O
7	Comparison of the Correct Use of Different Types of Inhalers in Patients with COPD and Bronchial Asthma. Tuberculosis and Lung Diseases, 2023, 101, 6-14.	0.7	0
8	Problems of medical care for patients with chronic obstructive pulmonary disease in the administrative territories of the Russian Federation. Profilakticheskaya Meditsina, 2023, 26, 76.	0.6	3
9	Status, problems and directions of improvement of pulmonological care for patients with chronic obstructive pulmonary disease according to the results of multicenter medical and sociological study. Pulmonologiya, 2023, 33, 517-524.	0.8	0
10	Radiation phenotypes of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus. Sibirskij žurnal KliniÄeskoj I Óksperimentalɹnoj Mediciny, 0, , .	0.4	O
11	Long-term oxygen therapy for chronic obstructive pulmonary disease: results from an observational cohort study. Meditsinskiy Sovet, 2023, , 86-94.	0.5	0
12	Federal Clinical Guidelines on Vaccination of pneumococcal infection in children and adults. Profilakticheskaya Meditsina, 2023, 26, 3.	0.6	1
13	Role of PI3K/AKT/mTOR signaling pathway and sirtuin genes in chronic obstructive pulmonary disease development. Vavilovskii Zhurnal Genetiki I Selektsii, 2023, 27, 512-521.	1.1	0
14	New concept and algorithm for the management of patients with chronic obstructive pulmonary disease. Pulmonologiya, 2023, 33, 587-594.	0.8	1
15	Course of sarcoidosis in patients treated with systemic corticosteroids. Pulmonologiya, 2023, 33, 634-644.	0.8	0
16	Optimization of pharmacotherapy of COPD patients using EURO FORTA and STOPP/START criteria. Kachestvennaya Klinicheskaya Praktika, 2023, , 55-65.	0.5	0
17	Medecines supply for patients with chronic obstructive pulmonary disease from the position of a clinical pharmacologist. Medical Technologies Assessment and Choice (ĐœĐμĐ Đ¸Ñ†Đ¸Đ½ÑĐºĐ¸Đμ Ñ,ĐμÑĐ½	D34 <b>5</b> %D34	ŧĐ <sup>Ŷ</sup> ии ĐžÑ†ŧ
18	Thyroid disfunction and chronic obstructive pulmonary disease: case report. Pulmonologiya, 2023, 33, 856-860.	0.8	O

#	Article	IF	CITATIONS
19	Ten-year analysis of the efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease. Pulmonologiya, 2023, 33, 750-758.	0.8	0
20	Efficacy of treatment of chronic obstructive pulmonary disease after virus-induced exacerbations. Pulmonologiya, 2023, 33, 739-749.	0.8	0
21	Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice. Pulmonologiya, 2023, 33, 109-118.	0.8	0
23	Analysis of the availability of bronchodilators and anti-inflammatory drugs for patients with chronic obstructive pulmonary disease. Farmakoekonomika, 2024, 17, 62-75.	1.2	0
24	Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19. Epidemiologiya I Vaktsinoprofilaktika, 2024, 23, 66-76.	0.8	0